Infused Therapy and Survival in Older Patients Diagnosed with Metastatic Breast Cancer who Received Trastuzumab

REFERENCES

• Genentech, Inc. Prescribing Information for Herceptin (trastuzumab). South San Francisco, CA: Genentech, Inc, 2009. http://www.gene.com/gene/products/information/pdf/herceptin-prescribing.pdf. Accessed October 7, 2010.
   Google Scholar
• Hudis CA. Trastuzumab—Mechanism of action and use in clinical practice. N Engl J Med 2007;357:39–51.
   PubMed Web of Science ®Google Scholar
• Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737–744.
   PubMed Web of Science ®Google Scholar
• Cobleigh MA, Vogel CL, Tripathy D, Nicholas RJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639–2648.
   PubMed Web of Science ®Google Scholar
• Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719–726.
   PubMed Web of Science ®Google Scholar
• Leyland-Jones B, Gelman K, Ayoub J-P, Arnold A, Verma S, Dias R, Ghahramani P. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 2003;21:3965–3971.
   PubMed Web of Science ®Google Scholar
• Baselga J, Carbonell X, Castaneda-Soto N-J, Clemens M, Green M, Harvey V, Morales S, Barton C, Ghahramani P. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005;23:2162–2171.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783–792.
   PubMed Web of Science ®Google Scholar
• Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Anton A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K, Extra J-M. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2—positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005;23:4265–4274.
   PubMed Web of Science ®Google Scholar
• Inoue K, Nakagami K, Mizutani M, Hozumi Y, Fujiwara Y, Masuda N, Tsukamoto F, Saito M, Miura S, Eguchi K, Shinkai T, Ando M, Watanabe T, Masuda N, Ohashi Y, Sano M, Noguchi S. Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the J017360 trial group. Breast Cancer Res Treat 2010;119:127–136.
   PubMed Web of Science ®Google Scholar
• Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence—SEER 17 Regs Limited-Use + Hurricane Katrina Impacted Louisiana Cases, Nov 2008 Sub (1973–2006 varying) –Linked To County Attributes—Total U.S., 1969–2006 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2009, based on the November 2008 submission.
   Google Scholar
• Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Medical Care 2002;40(suppl):IV-3–IV-18.
   Google Scholar
• National Cancer Institute (NCI). Overview of the SEER program [Internet]. Bethesda, MD: NCI, 2010. http://seer.cancer.gov/about. Accessed October 7, 2010.
   Google Scholar
• National Cancer Institute (NCI). SEER-Medicare: How the SEER & Medicare data are Linked [Internet]. Bethesda, MD: NCI, 2010. http://healthservices.cancer.gov/seermedicare/overview/linked.html. Accessed October 7, 2010.
   Google Scholar
• Earle CC, Nattinger AB, Potosky AL, Lang K, Mallick R, Berger M, Warren JL. Identifying cancer relapse using SEER-Medicare Data. Medical Care 2002;40(8)(suppl):IV-75–IV-81.
   Web of Science ®Google Scholar
• Stokes ME, Thompson D, Montoya EL, Weinstein MC, Winder EP, Earle CC. Ten-year survival and cost following breast cancer recurrence: estimates from SEER-Medicare data. Value in Health 2008;11:213–220.
   PubMed Web of Science ®Google Scholar
• Practice Management Information Corporation (PMIC). ICD-9-CM, 6th ed. Los Angeles, CA: Practice Management Information Corporation, 2005.
   Google Scholar
• Practice Management Information Corporation. HCPCS. Los Angeles, CA: PMIC, 2005.
   Google Scholar
• Warren JL, Harlan LC, Fahey BA, Freeman JL, Klabunde CN, Cooper GS, Knopf KB. Utility of the SEER-Medicare data to identify chemotherapy use. Medical Care 2002;40(8)(suppl):IV-55–IV-61.
   Web of Science ®Google Scholar
• National Cancer Institute (NCI). Procedure codes for SEER-Medicare analysis [internet]. Bethesda, MD: NCI, 2010. http://healthservices.cancer.gov/seermedicare/considerations/procedure-codes.html. Accessed July 12, 2010.
   Google Scholar
• ResDAC Research Data Assistance Center. CMS 301: Using SEER/Medicare data for research. Minneapolis, MN: ResDAC.
   Google Scholar
• Giordano SH, Kuo Y-F, Duan Z, Hortobagyi, GN, Freeman J, Goodwin JS. Limits of observational data in dertermining outcomes from cancer therapy. Cancer 2008;112:2456–2466.
   PubMed Web of Science ®Google Scholar
• Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000;53:1258–1267.
   PubMed Web of Science ®Google Scholar
• Fritz A, Ries L, (eds.). SEER Program Code Manual, 3rd edition. Bethesda, MD: Cancer Statistics Branch, Surveillance Program, Div of Cancer Control and Pop Sciences, National Cancer Institute, National Institutes of Health, Public Health Service, U.S. Deptartment of Health and Human Services, 1998. http://seer.cancer.gov/manuals/codeman.pdf. Accessed October 7, 2010.
   Google Scholar
• National Cancer Institute (NCI). SAS macro to remove unreliable diagnosis coding. Bethesda, MD: Author. http://healthservices.cancer.gov/seermedicare/program/remove.ruleout.dxcodes.macro. txt. Accessed May 25, 2010.
   Google Scholar
• National Cancer Institute (NCI). SAS macro to calculate a comorbidity index for a patient with respect to cancer. NCI http://healthservices.cancer.gov/seermedicare/program/charlson.comorbidity.macro.txt. Accessed May 25, 2010.
   Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987;40(5):373–383.
   PubMedGoogle Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613–619.
   PubMed Web of Science ®Google Scholar
• Romano PS, Roos LL, Luft HS, Jollis JG, Doliszny K. A comparison of administrative versus clinical data: coronary artery bypass surgery as an example. J Clin Epidemiol 1994;47:249–260.
   PubMed Web of Science ®Google Scholar
• Salloum RG, Smith TJ, Jensen GA, Elston Lafata J. Using claims-based measures to predict performance status score in patients with lung cancer. Cancer 2010;117:1038–1048.
   PubMed Web of Science ®Google Scholar
• Virnig BA, Warren JL, Cooper GS, Klabunde CN, Schussler N, Freeman J. Studying radiation therapy using SEER-Medicare-linked data. Medical Care 2002;40(8)(suppl):IV-49–IV-54.
   Web of Science ®Google Scholar
• Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127:757–763.
   PubMed Web of Science ®Google Scholar
• Suissa S. Immortal time bias in pharmacoepidemiology. Am J Epidemiol 2008;167:492–499.
   PubMed Web of Science ®Google Scholar
• Swihart BJ, Caffo B, James BD, Strand M, Schwartz BS, Punjabi NM. Lasagna plots: a saucy alternative to spagetti plots. Epidemiology 2010;21(5):621–625.
   PubMed Web of Science ®Google Scholar
• Hadley J, Yabroff KR, Barrett MJ, Penson DF, Saigal CS, Potosky AL. Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data. J Natl Cancer Inst 2010;102:1780–1793.
   PubMed Web of Science ®Google Scholar
• Bosco JLF, Silliman RA, Thwin SS, Geiger AM, Buist DS, Prout MN, Yood MU, Haque R, Wei F, Lash TL. A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. J Clin Epidemiol. 2010;63:64–74.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177–182.
   PubMed Web of Science ®Google Scholar
• Siegel J. Approval of biologics license application for Trastu- zumab, 1998. http://www.fda.gov/downloads/Drugs/Development ApprovalProcess/HowDrugsareDevelopedandApproved/Approval Applications/TherapeuticBiologicApplications/ucm091360.pdf. Accessed October 7, 2010.
   Google Scholar
• Cooper GS, Yuan Z, Stange KC, Amini SB, Dennis LK, Rimm AA. The utility of Medicare claims data for measuring cancer stage. Medical Care 1999;37(7):706–711.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005;365(9472):1687–1717.
   PubMed Web of Science ®Google Scholar